Featured Article


Conflict of Interest: An Ethical Firestorm with Consequences for Cancer Research
Bruce A. Chabner, Susan E. Bates
The Oncologist 2018; 23:1391-1393; first published on October 23, 2018; doi:10.1634/theoncologist.2018-0662

Recent Translated Articles from The Oncologist

Volume 24: Number 1, January, 2019

Clinical Trial Results

关于 JAK1 抑制剂 Itacitinib 和白蛋白结合型紫杉醇及吉西他滨联合治疗晚期实体肿瘤的 Ib/II 期研究
A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors
Gregory L. Beatty, Safi Shahda, Thaddeus Beck, Nikhil Uppal, Steven J. Cohen, Ross Donehower, Afshin Eli Gabayan, Albert Assad, Julie Switzky, Huiling Zhen, Daniel D. Von Hoff
The Oncologist 2019; 24:14-e10; first published on August 16, 2018; doi:10.1634/theoncologist.2017-0665

凡德他尼和硼替佐米用于局部晚期或转移性甲状腺髓样癌成年患者的I/II 期试验
Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer
Jaydira Del Rivero, Maureen Edgerly, Jean Ward, Ravi A. Madan, Sanjeeve Balasubramaniam, Tito Fojo, Ann W. Gramza
The Oncologist 2019; 24:16-e14; first published on October 8, 2018; doi:10.1634/theoncologist.2018-0452

比较紫杉醇与伊立替康在一线治疗失败的转移性或复发性胃癌患者中的有效性和安全性的 III 期研究(KCSG ST10-01)
A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)
Keun‐Wook Lee, Chi Hoon Maeng, Tae‐You Kim, Dae Young Zang, Yeul Hong Kim, In Gyu Hwang, Sang Cheul Oh, Joo Seop Chung, Hong Suk Song, Jin Won Kim, Su Jin Jeong, Jae Yong Cho
The Oncologist 2019; 24:18-e24; first published on August 20, 2018; doi:10.1634/theoncologist.2018-0142

帕唑帕尼用于转移性腺泡状软组织肉瘤患者的I/II 期试验
A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
Miso Kim, Tae Min Kim, Bhumsuk Keam, Yu Jung Kim, Jin Chul Paeng, Kyung Chul Moon, Dong‐Wan Kim, Dae Seog Heo
The Oncologist 2019; 24:20-e29; first published on September 25, 2018; doi:10.1634/theoncologist.2018-0464

Breast Cancer

基于 3' 非翻译区的整合模型识别可手术的三阴性乳腺癌腋窝淋巴结转移低风险的患者
Integrative 3′ Untranslated Region‐Based Model to Identify Patients with Low Risk of Axillary Lymph Node Metastasis in Operable Triple‐Negative Breast Cancer
Lei Wang, Xin Hu, Peng Wang, Zhi‐Ming Shao
The Oncologist 2019; 24:22-30; first published on August 6, 2018; doi:10.1634/theoncologist.2017-0609

Impact of Guideline‐Discordant Treatment on Cost and Health Care Utilization in Older Adults with Early‐Stage Breast Cancer
Courtney P. Williams, Kelly M. Kenzik, Andres Azuero, Grant R. Williams, Maria Pisu, Karina I. Halilova, Stacey A. Ingram, Supriya K. Yagnik, Andres Forero, Smita Bhatia, Gabrielle B. Rocque
The Oncologist 2019; 24:31-37; first published on August 17, 2018; doi:10.1634/theoncologist.2018-0076

Regulatory Issues: FDA

FDA 批准摘要:派姆单抗用于治疗复发性局部晚期或转移性胃或胃食管连接部腺癌(表达 PD-L1)
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
Lola Fashoyin‐Aje, Martha Donoghue, Huanyu Chen, Kun He, Janaki Veeraraghavan, Kirsten B. Goldberg, Patricia Keegan, Amy E. McKee, Richard Pazdur
The Oncologist 2019; 24:103-109; first published on August 17, 2018; doi:10.1634/theoncologist.2018-0221

Head and Neck Cancers

鼻咽癌患者调强放疗对比二维放疗的10 年治疗比结果
10‐Year Results of Therapeutic Ratio by Intensity‐Modulated Radiotherapy Versus Two‐Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma
Lei Chen, Yuan Zhang, Shu‐Zhen Lai, Wen‐Fei Li, Wei‐Han Hu, Rui Sun, Li‐Zhi Liu, Fan Zhang, Hao Peng, Xiao‐Jing Du, Ai‐Hua Lin, Ying Sun, Jun Ma
The Oncologist 2019; 24:e38-e45; first published on August 6, 2018; doi:10.1634/theoncologist.2017-0577